Aung Naing, MD, Discusses Strategies for the Effective Management of IRAEs
The increasing use of checkpoint inhibitors and other immunotherapies has created a need for the development of a cohesive education program and list of guidelines for treating common toxicities.
While the increasing use of immunotherapies has revolutionized cancer care and led to deeper and durable treatment responses, those results can sometimes come with the unwanted cost of severe immune-related adverse events (IRAEs).
In an interview with CancerNetwork®, Aung Naing, MD, of The University of Texas MD Anderson Cancer Center, discussed his recently published review of strategies for improving the management of these IRAEs, along with his recommendations for developing standardized measures of effective management, accessible to both community and academic cancer care teams. Naing emphasized the need to provide proper patient education and harmonize management guidelines and reporting of IRAEs.
“There is room for further improvement,” Naing said of the management of IRAEs. “We look forward to working with our colleagues in immuno-oncology to develop these strategies that will minimize the toxic effects of immune checkpoint inhibitors.”
This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.
Reference:
Naing A, Hajjar J, Gulley JL, et al. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020;8(2):e001754. doi:10.1136/jitc-2020-001754
Viability and Future of Maintenance Therapy in Solid Tumors
April 6th 2022Shilpa Gupta, MD, and Jason R. Brown, MD, PhD, discuss a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.
